Zika Virus Epidemiology: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Camila Xu and Version 1 by Sathish Kumar Natarajan.

Zika virus (ZIKV) is a Flavivirus and was first isolated in a sentinel monkey kept for studying mosquito-borne diseases, and was also later isolated from Aedes africanus mosquitoes, confirming its vector-borne transmission, in the Ziika forest of Uganda.

  • apoptosis
  • placenta
  • ER stress

1. Introduction

Zika virus (ZIKV) is a Flavivirus and was first isolated in a sentinel monkey kept for studying mosquito-borne diseases, and was also later isolated from Aedes africanus mosquitoes, confirming its vector-borne transmission, in the Ziika forest of Uganda [1]. Intracerebral inoculations of ZIKV in young mice showed extensive neurological lesions, while inoculation from the mice to non-human primates resulted in a self-limiting febrile condition in a few subjects. Later, neutralizing antibodies were found in both humans and monkeys on serological screenings [2]. The first human case was reported during the isolation process of the virus, wherein the clinical signs were described as pyrexia along with rashes by Simpson et al. in 1964 [3]. The occurrence of neurological abnormalities in infants born to pregnant mothers infected with ZIKV created concern regarding disease outbreak [4]. Currently, there is no Food and Drug Administration (FDA) approved vaccine or treatment for ZIKV infection.

2. ZIKV Epidemiology

The first widespread cluster of ZIKV outbreaks was reported from Yap Island in Micronesia [5]. Around 2013–2014, another outbreak with a considerable number of infections occurred in French Polynesia [6]. Reports of various modes of transmission other than mosquitoes and involvement of neurological disorders such as Guillain-Barre syndrome in a subset of the population were also observed during this outbreak [7,8][7][8]. The presence of vectors and travel-related introductions of ZIKV to a population without any prior exposure, along with other existing arboviral infections such as dengue and Chikungunya, may have favored the increased transmission of disease observed in the recent outbreaks [9,10,11,12][9][10][11][12]. In 2015 ZIKV had spread to Brazil, and later ZIKV spread to other parts of the American continent including Colombia, Honduras, Puerto Rico, the Dominican Republic, Jamaica, and Haiti [13]. In the mainland of the United States of America (USA), cases were also reported in the state of Florida in 2016 [14]

2.1. ZIKV Strains

Genetic changes in the ZIKV, involving complex interactions between the vector, human populations and non-human primate populations led to the evolution of the virus [15]. Two lineages of ZIKV are (1) Asian origin and (2) African origin. The African strain has two groups, the Ugandan versus the Nigerian group. The strain originally isolated from Rhesus macaque in the Ziika forest is MR-766, whereas IbH is the first strain isolated from the human blood in Nigeria [16]. The first isolated Asian ZIKV strain is from Malaysia with the prototype strain P6-740, and the cluster includes strains from Cambodia, French Polynesia and other Asian countries. In addition, some reports describe that the African strain is more cytotoxic to placental cells than Asian strains but both strains showed similar replicative efficiency [17]. ZIKV strains in the American continent that circulated from the 2015–2016 Brazil outbreak, evolved from the Asian lineage [18]. Travel-related to major sports events could have contributed to the spread of the virus from Pacific islands including French Polynesia to Brazil [19]. The presence of a new glycosylation motif in an asparagine residue at position 154 of envelope protein in the 2007 Yap strain- EC Yap and the French Polynesian H/PF/2013 strain could possibly explain the gain in their virulence when compared to MR766 which does not have this glycosylation motif [8].

2.2. Transmission of ZIKV

Usually, the disease is spread by the bite of the infected mosquito (Aedes aegypti, Aedes albopictus) [20]. The infection can also be vertically transmitted from infected mother to fetus. It can also be sexually transmitted, as ZIKV RNA is detected in semen samples of infected patients even after 6 months of infection [21[21][22],22], although only 3% of the total ZIKV cases account for sexually transmitted cases and a study suggests that semen suppresses the binding of ZIKV to cells [23]. Blood transfusions from infected individuals could also be a potential source of ZIKV infection early in the epidemic [24]. The virus replicates in the epithelial cells of the mosquitoes’ gut and later spreads to the mosquitoes’ salivary gland: then, the virus spreads to humans via a mosquito bite [25,26][25][26]. The receptors in the dermal fibroblasts, immature dendritic cells and keratinocytes facilitate viral entry and support viral replication [27]. Wild macaques are naturally susceptible to ZIKV infection [28]. The arbovirus infection follows a sylvatic cycle with non-human primates as the reservoir of the virus [29]. They serve as the connecting bridge for ZIKV circulation among mosquitoes and transmission to humans due to the extensive urbanization in the present-day scenario [30].

2.3. ZIKV Structure

ZIKV is icosahedral in symmetry, ~40 nm with a nucleocapsid ~25–30 nm and surface projections ~5–10 nm [31,32][31][32]. Its genome is 10.8 Kb with 5′ NCR (translation via a methylated nucleotide cap or a genome-linked protein) and 3′ NCR (translation, RNA packaging, cyclization, genome stabilization and recognition)[33,34,35][33][34][35]. The virion consists of an envelope (E protein) covering the majority of the surface with non-structural proteins NS1 for virion production, NS3, and NS5 are large, highly conserved proteins, NS2A, NS2B, NS4A, and NS4B are small, hydrophobic proteins and NS4B, NS5 are targets for evolution [35,36,37][35][36][37]. Functions of individual ZIKV proteins are enlisted in Table 1.
Table 1.
Zika viral proteins and their function.
Protein Function
Envelope (E) Host cell binding and membrane fusion [38]
Capsid Viral protein surrounds nucleic acid [39]
Membrane protein Proteolytic cleavage of a pre membrane protein from membrane protein in the Golgi apparatus results in the release of the virus [40]
NS1 RNA replication [41]
NS2A Modulates different components of the virus during assembly [42]
NS2B Cofactor of NS3 protease [43]
NS3 Protease and helicase domain for polyprotein possessing & nucleoside triphosphtase (NTPase)/RNA triphosphatase (RTPase) activities [43]
NS4A Evasion of the innate immune response, associated with replication complex [44,45]Evasion of the innate immune response, associated with replication complex [44][45]
NS4B Evasion of the innate immune response [46]
NS5 Methyl transferase (MTase) and RNA dependent RNA polymerase (RdRp) [47]

2.4. ZIKV Replication

Virus entry into the cell occurs by the initial recognition of host receptors by glycosylated regions on the envelope protein of the ZIKV [48]. Endocytosis of the infectious viral particle occurs by clathrin-coated vesicles. A low pH environment within the endosome facilitates conformational changes in the envelope protein of the virus, resulting in fusion to the endosome and thereby releasing the positive-strand RNA of the virus [47]. The positive strand becomes translated in the endoplasmic reticulum of the host cells into a polyprotein that is cleaved by the host cell proteases and the viral non-structural proteins such as NS3 and NS2B, which is a co-factor for protease. Non-structural proteins NS5 (RNA-dependent RNA polymerase) and NS3 (helicase) also replicate the positive-sense RNA strand to form a negative-sense RNA strand [49]. The negative-sense RNA strand serves as a template for further production of a new positive sense RNA strand. The newly produced positive sense RNA strand can either be translated or further used for viral genome replication [50]. After the assembly of structural proteins around the viral genome, they are translocated to the Golgi apparatus where they become mature virions by cleavage of the precursor membrane protein and exit the host cell [51] (Figure 1).
Nutrients 15 00124 g001
Figure 1. Schematic representation of nutraceuticals role in blocking ZIKV replication. Number 1–9 represent different stages of ZIKV infection, viral assembly, new viral formation, and release of mature virus from the infected cells. Nutrients compound identified that are known to inhibit various stages of viral infection are listed in the box inserts. ssRNA, single stranded ribonucleic acid; ERGIC, ER-Golgi intermediate compartment; RdRp, RNA dependent RNA polymerase; ROS, Reactive oxygen species; nsps, non-structural proteins of Zika virus.

2.5. Clinical Findings and Congenital Zika Syndrome

In normal healthy children and adults, ZIKV infection usually presents with a mild febrile disease with rashes and joint pain [52]. Pregnant women typically develop symptoms such as rashes during ZIKV infection [53]. ZIKV infection in pregnant women results in both congenital brain defects and ocular defects in the fetus. Brain defects include microcephaly, cerebral atrophy, subcortical calcifications, agyria, hydrocephalus and ventriculomegaly [54]. Ocular defects include microphthalmia, optic nerve defects, cataract, and intraocular calcifications. Congenital contractures, reduced musculoskeletal movements, dysphagia, hypertonia, hypotonia, seizures and irritability are also reported in infants with in utero ZIKV infection [55]. Further, a case-control study showed that women with ZIKV infection during the early stages of pregnancy were more likely to have babies with congenital Zika syndrome (CZS) [56]. ZIKV infection is also associated with the development of Guillain-Barre syndrome in some adults, which is an autoimmune condition affecting the nervous system [57].

2.6. Diagnosis, Treatment, and Prevention of ZIKV Infection

In suspected ZIKV cases, a diagnosis is usually based on laboratory confirmation using IgM detecting serological test or RT-PCR based on E and NS2B genes [58,59,60][58][59][60]. In a particular place when there are ongoing outbreaks, it is recommended for pregnant women to be tested for ZIKV infection [61]. Serology tests can detect ZIKV as early as one week after suspected infection, but cross-reacting antibodies from other Flaviviruses can result in false-positive serological results [62]. Measuring viral RNA copy number using RT-PCR can also be used to detect the initial viremia in urine samples, cord blood and placental samples at delivery [63]. Currently, there is no approved vaccine for the effective prevention of the disease [64]. Only supportive treatment is available if infected [65]. Implementing effective mosquito control strategies in places with ZIKV infection is crucial to break the chain of ongoing disease spread [66]. Avoiding travel to areas with ongoing ZIKV outbreaks, especially if pregnant or planning to become pregnant are some of the ways to reduce the risk of infection [67]. There us ab option of using genetically modified Aedes aegypti mosquitoes to reduce the population of wild type mosquitoes to control mosquito-borne disease, but it is considered an emerging risk [68]

2.7. ZIKV Vaccines and Drug Development

ZIKV vaccine development is challenged by the target audience; it must be safe for pregnant women and to prevent neurological disorders in adults and fetuses [69,70][69][70]. Despite the challenges, several vaccine candidates have entered preclinical animal studies and phase I clinical trials. Some of the vaccine candidates which have entered phase I clinical trials that are noteworthy to mention include DNA vaccines by Inovio Pharmaceuticals and NIH, whole purified inactivated vaccine by WRAIR/Sanofi Pasteur Limited and Live, Dengue virus vectored vaccine by Butantan Institute [69]. Another major issue in vaccine development and translation of the vaccine technology into use is that ZIKV outbreaks had waned, making it too challenging to test the effectiveness of the vaccine without ongoing active disease transmission, along with the slow decline in funding which supports vaccine development [71]. Several drug repurposing studies have been conducted and found to be effective against ZIKV infection. However, there are no FDA-approved drugs available for ZIKV infection because most of the drugs do not have enough data to support safety in pregnant women. Examples of existing drugs with anti-ZIKV activity are suramin, nitazoxanide, chloroquine (anti-protozoal drugs), niclosamide, ivermectin (anthelmintics), mycophenolic acid (an immunosuppressant drug), PHA-690509 (cyclin-dependent kinase inhibitor) and sofosbuvir (an anti-viral drug effective against hepatitis C virus, [72]. Sofosbuvir has shown promising results in preventing ZIKV transmission from mother to fetus in pregnant mice and pregnant non-human primate models [73,74][73][74]. Interestingly, for some phytochemical compounds a computation approach shows that Polydatin, Liquiritin, Cichoriin, Dihydrogenistin and Rhapontin shows high docking score compared to the Sofosbuvir. Especially, Polydatin has more capacity for receptor binding when compared to Sofosbuvir (Table 2). Thus, phytochemicals can be used as a cost-effective ZIKV inhibitors; however, biocompatibility and effectiveness have to be proved in non-computational research experiments [75].

 

References

  1. Dick, G.W.; Kitchen, S.F.; Haddow, A.J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 1952, 46, 509–520.
  2. Dick, G.W.A. Zika virus (II). Pathogenicity and physical properties. Trans. R. Soc. Trop. Med. Hyg. 1952, 46, 521–534.
  3. Simpson, D.I.H. Zika virus infection in man. Trans. R. Soc. Trop. Med. Hyg. 1964, 58, 335–338.
  4. Smith, D.E.; Beckham, J.D.; Tyler, K.L.; Pastula, D.M. Zika virus disease for neurologists. Neurol. Clin. Pract. 2016, 6, 515–522.
  5. Duffy, M.R.; Chen, T.H.; Hancock, W.T.; Powers, A.M.; Kool, J.L.; Lanciotti, R.S.; Pretrick, M.; Marfel, M.; Holzbauer, S.; Dubray, C.; et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 2009, 360, 2536–2543.
  6. Cao-Lormeau, V.-M.; Roche, C.; Teissier, A.; Robin, E.; Berry, A.-L.; Mallet, H.-P.; Sall, A.A.; Musso, D. Zika virus, French polynesia, South pacific, 2013. Emerg. Infect. Dis. 2014, 20, 1085–1086.
  7. Oehler, E.; Watrin, L.; Larre, P.; Leparc-Goffart, I.; Lastere, S.; Valour, F.; Baudouin, L.; Mallet, H.; Musso, D.; Ghawche, F. Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013. Euro Surveill. Bull. Eur. Mal. Transm. = Eur. Commun. Dis. Bull. 2014, 19, 20720.
  8. Musso, D.; Gubler, D.J. Zika Virus. Clin. Microbiol. Rev. 2016, 29, 487–524.
  9. Kama, M.; Aubry, M.; Naivalu, T.; Vanhomwegen, J.; Mariteragi-Helle, T.; Teissier, A.; Paoaafaite, T.; Hue, S.; Hibberd, M.L.; Manuguerra, J.C.; et al. Sustained Low-Level Transmission of Zika and Chikungunya Viruses after Emergence in the Fiji Islands. Emerg. Infect. Dis. 2019, 25, 1535–1538.
  10. Calvez, E.; Mousson, L.; Vazeille, M.; O’Connor, O.; Cao-Lormeau, V.-M.; Mathieu-Daudé, F.; Pocquet, N.; Failloux, A.-B.; Dupont-Rouzeyrol, M. Zika virus outbreak in the Pacific: Vector competence of regional vectors. PLoS Negl. Trop. Dis. 2018, 12, e0006637.
  11. Delatorre, E.; Fernandez, J.; Bello, G. Investigating the Role of Easter Island in Migration of Zika Virus from South Pacific to Americas. Emerg. Infect. Dis. 2018, 24, 2119–2121.
  12. Pettersson, J.H.O.; Eldholm, V.; Seligman, S.J.; Lundkvist, Å.; Falconar, A.K.; Gaunt, M.W.; Musso, D.; Nougairède, A.; Charrel, R.; Gould, E.A.; et al. How Did Zika Virus Emerge in the Pacific Islands and Latin America? mBio 2016, 7, e01239-16.
  13. Metsky, H.C.; Matranga, C.B.; Wohl, S.; Schaffner, S.F.; Freije, C.A.; Winnicki, S.M.; West, K.; Qu, J.; Baniecki, M.L.; Gladden-Young, A.; et al. Zika virus evolution and spread in the Americas. Nature 2017, 546, 411–415.
  14. Likos, A.; Griffin, I.; Bingham, A.M.; Stanek, D.; Fischer, M.; White, S.; Hamilton, J.; Eisenstein, L.; Atrubin, D.; Mulay, P.; et al. Local Mosquito-Borne Transmission of Zika Virus—Miami-Dade and Broward Counties, Florida, June-August 2016. MMWR. Morb. Mortal. Wkly. Rep. 2016, 65, 1032–1038.
  15. Beaver, J.T.; Lelutiu, N.; Habib, R.; Skountzou, I. Evolution of Two Major Zika Virus Lineages: Implications for Pathology, Immune Response, and Vaccine Development. Front. Immunol. 2018, 9, 1640.
  16. Haddow, A.D.; Schuh, A.J.; Yasuda, C.Y.; Kasper, M.R.; Heang, V.; Huy, R.; Guzman, H.; Tesh, R.B.; Weaver, S.C. Genetic characterization of Zika virus strains: Geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis. 2012, 6, e1477.
  17. Sheridan, M.A.; Balaraman, V.; Schust, D.J.; Ezashi, T.; Roberts, R.M.; Franz, A.W.E. African and Asian strains of Zika virus differ in their ability to infect and lyse primitive human placental trophoblast. PLoS ONE 2018, 13, e0200086.
  18. Enfissi, A.; Codrington, J.; Roosblad, J.; Kazanji, M.; Rousset, D. Zika virus genome from the Americas. Lancet 2016, 387, 227–228.
  19. Musso, D. Zika Virus Transmission from French Polynesia to Brazil. Emerg. Infect. Dis. 2015, 21, 1887.
  20. Li, M.I.; Wong, P.S.; Ng, L.C.; Tan, C.H. Oral susceptibility of Singapore Aedes (Stegomyia) aegypti (Linnaeus) to Zika virus. PLoS Negl. Trop. Dis. 2012, 6, e1792.
  21. Foy, B.D.; Kobylinski, K.C.; Chilson Foy, J.L.; Blitvich, B.J.; Travassos da Rosa, A.; Haddow, A.D.; Lanciotti, R.S.; Tesh, R.B. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 2011, 17, 880–882.
  22. Mead, P.S.; Duggal, N.K.; Hook, S.A.; Delorey, M.; Fischer, M.; Olzenak McGuire, D.; Becksted, H.; Max, R.J.; Anishchenko, M.; Schwartz, A.M.; et al. Zika Virus Shedding in Semen of Symptomatic Infected Men. N. Engl. J. Med. 2018, 378, 1377–1385.
  23. Müller, J.A.; Harms, M.; Krüger, F.; Groß, R.; Joas, S.; Hayn, M.; Dietz, A.N.; Lippold, S.; von Einem, J.; Schubert, A.; et al. Semen inhibits Zika virus infection of cells and tissues from the anogenital region. Nat. Commun. 2018, 9, 2207.
  24. Sharma, A.; Lal, S.K. Zika Virus: Transmission, Detection, Control, and Prevention. Front. Microbiol. 2017, 8, 110.
  25. Elizondo-Quiroga, D.; Medina-Sánchez, A.; Sánchez-González, J.M.; Eckert, K.A.; Villalobos-Sánchez, E.; Navarro-Zúñiga, A.R.; Sánchez-Tejeda, G.; Correa-Morales, F.; González-Acosta, C.; Arias, C.F.; et al. Zika Virus in Salivary Glands of Five Different Species of Wild-Caught Mosquitoes from Mexico. Sci. Rep. 2018, 8, 809.
  26. Mourya, D.T.; Gokhale, M.D.; Majumdar, T.D.; Yadav, P.D.; Kumar, V.; Mavale, M.S. Experimental Zika virus infection in Aedes aegypti: Susceptibility, transmission & co-infection with dengue & chikungunya viruses. Indian J. Med. Res. 2018, 147, 88–96.
  27. Routhu, N.K.; Byrareddy, S.N. Host-Virus Interaction of ZIKA Virus in Modulating Disease Pathogenesis. J. Neuroimmune Pharm. 2017, 12, 219–232.
  28. Newman, C.; Friedrich, T.C.; O’Connor, D.H. Macaque monkeys in Zika virus research: 1947-present. Curr. Opin. Virol. 2017, 25, 34–40.
  29. Althouse, B.M.; Vasilakis, N.; Sall, A.A.; Diallo, M.; Weaver, S.C.; Hanley, K.A. Potential for Zika Virus to Establish a Sylvatic Transmission Cycle in the Americas. PLoS Negl. Trop. Dis. 2016, 10, e0005055.
  30. Terzian, A.C.B.; Zini, N.; Sacchetto, L.; Rocha, R.F.; Parra, M.C.P.; Del Sarto, J.L.; Dias, A.C.F.; Coutinho, F.; Rayra, J.; da Silva, R.A.; et al. Evidence of natural Zika virus infection in neotropical non-human primates in Brazil. Sci. Rep. 2018, 8, 16034.
  31. Passi, D.; Sharma, S.; Dutta, S.R.; Ahmed, M. Zika Virus Diseases—The New Face of an Ancient Enemy as Global Public Health Emergency (2016): Brief Review and Recent Updates. Int. J. Prev. Med. 2017, 8, 6.
  32. Sirohi, D.; Chen, Z.; Sun, L.; Klose, T.; Pierson, T.C.; Rossmann, M.G.; Kuhn, R.J. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 2016, 352, 467–470.
  33. Basile, K.; Kok, J.; Dwyer, D.E. Zika virus: What, where from and where to? Pathology 2017, 49, 698–706.
  34. Faye, O.; Freire, C.C.; Iamarino, A.; Faye, O.; de Oliveira, J.V.; Diallo, M.; Zanotto, P.M.; Sall, A.A. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl. Trop. Dis. 2014, 8, e2636.
  35. Lee, I.; Bos, S.; Li, G.; Wang, S.; Gadea, G.; Desprès, P.; Zhao, R.Y. Probing Molecular Insights into Zika Virus⁻Host Interactions. Viruses 2018, 10, 233.
  36. Lindenbach, B.D.; Rice, C.M. Molecular biology of flaviviruses. Adv. Virus Res. 2003, 59, 23–61.
  37. Sironi, M.; Forni, D.; Clerici, M.; Cagliani, R. Nonstructural Proteins Are Preferential Positive Selection Targets in Zika Virus and Related Flaviviruses. PLoS Negl. Trop. Dis. 2016, 10, e0004978.
  38. Chellasamy, S.K.; Devarajan, S. Identification of Potential Lead Molecules for Zika Envelope Protein from In Silico Perspective. Avicenna J. Med. Biotechnol. 2019, 11, 94–103.
  39. Tan, T.Y.; Fibriansah, G.; Kostyuchenko, V.A.; Ng, T.-S.; Lim, X.-X.; Zhang, S.; Lim, X.-N.; Wang, J.; Shi, J.; Morais, M.C.; et al. Capsid protein structure in Zika virus reveals the flavivirus assembly process. Nat. Commun. 2020, 11, 895.
  40. Nambala, P.; Su, W.-C. Role of Zika Virus prM Protein in Viral Pathogenicity and Use in Vaccine Development. Front. Microbiol. 2018, 9, 1797.
  41. Moreira-Soto, A.; de Souza Sampaio, G.; Pedroso, C.; Postigo-Hidalgo, I.; Berneck, B.S.; Ulbert, S.; Brites, C.; Netto, E.M.; Drexler, J.F. Rapid decline of Zika virus NS1 antigen-specific antibody responses, northeastern Brazil. Virus Genes 2020, 56, 632–637.
  42. Zhang, X.; Xie, X.; Zou, J.; Xia, H.; Shan, C.; Chen, X.; Shi, P.Y. Genetic and biochemical characterizations of Zika virus NS2A protein. Emerg. Microbes Infect. 2019, 8, 585–602.
  43. Hilgenfeld, R.; Lei, J.; Zhang, L. The Structure of the Zik.ka Virus Protease, NS2B/NS3pro. In Dengue and Zika: Control and Antiviral Treatment Strategies; Hilgenfeld, R., Vasudevan, S.G., Eds.; Springer: Singapore, 2018; pp. 131–145.
  44. Hu, Y.; Dong, X.; He, Z.; Wu, Y.; Zhang, S.; Lin, J.; Yang, Y.; Chen, J.; An, S.; Yin, Y.; et al. Zika virus antagonizes interferon response in patients and disrupts RIG-I–MAVS interaction through its CARD-TM domains. Cell Biosci. 2019, 9, 46.
  45. Rodriguez, A.K.; Muñoz, A.L.; Segura, N.A.; Rangel, H.R.; Bello, F. Molecular characteristics and replication mechanism of dengue, zika and chikungunya arboviruses, and their treatments with natural extracts from plants: An updated review. EXCLI J. 2019, 18, 988–1006.
  46. Ngueyen, T.T.N.; Kim, S.J.; Lee, J.Y.; Myoung, J. Zika Virus Proteins NS2A and NS4A Are Major Antagonists that Reduce IFN-β Promoter Activity Induced by the MDA5/RIG-I Signaling Pathway. J. Microbiol. Biotechnol. 2019, 29, 1665–1674.
  47. Wang, B.; Thurmond, S.; Hai, R.; Song, J. Structure and function of Zika virus NS5 protein: Perspectives for drug design. Cell. Mol. Life Sci. CMLS 2018, 75, 1723–1736.
  48. Routhu, N.K.; Lehoux, S.D.; Rouse, E.A.; Bidokhti, M.R.M.; Giron, L.B.; Anzurez, A.; Reid, S.P.; Abdel-Mohsen, M.; Cummings, R.D.; Byrareddy, S.N. Glycosylation of Zika Virus is Important in Host-Virus Interaction and Pathogenic Potential. Int. J. Mol. Sci. 2019, 20, 5206.
  49. Šebera, J.; Dubankova, A.; Sychrovský, V.; Ruzek, D.; Boura, E.; Nencka, R. The structural model of Zika virus RNA-dependent RNA polymerase in complex with RNA for rational design of novel nucleotide inhibitors. Sci. Rep. 2018, 8, 11132.
  50. Sager, G.; Gabaglio, S.; Sztul, E.; Belov, G.A. Role of Host Cell Secretory Machinery in Zika Virus Life Cycle. Viruses 2018, 10, 559.
  51. Heinz, F.X.; Stiasny, K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol. Mol. Biol. Rev. 2017, 81, e00055-16.
  52. Pierson, T.C.; Diamond, M.S. The emergence of Zika virus and its new clinical syndromes. Nature 2018, 560, 573–581.
  53. Rawlinson, W. Pregnancy, the placenta and Zika virus (ZIKV) infection. Microbiol. Aust. 2016, 37, 170–172.
  54. Moore, C.A.; Staples, J.E.; Dobyns, W.B.; Pessoa, A.; Ventura, C.V.; Fonseca, E.B.d.; Ribeiro, E.M.; Ventura, L.O.; Neto, N.N.; Arena, J.F.; et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr. 2017, 171, 288–295.
  55. Oeser, C.; Ladhani, S. An update on Zika Virus and Congenital Zika Syndrome. Paediatr. Child. Health 2019, 29, 34–37.
  56. Lima, G.P.; Rozenbaum, D.; Pimentel, C.; Frota, A.C.C.; Vivacqua, D.; Machado, E.S.; Sztajnbok, F.; Abreu, T.; Soares, R.A.; Hofer, C.B. Factors associated with the development of Congenital Zika Syndrome: A case-control study. BMC Infect. Dis. 2019, 19, 277.
  57. Barbi, L.; Coelho, A.V.C.; Alencar, L.C.A.; Crovella, S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: A systematic review and meta-analysis. Braz. J. Infect. Dis. Off. Publ. Braz. Soc. Infect. Dis. 2018, 22, 137–141.
  58. St George, K.; Sohi, I.S.; Dufort, E.M.; Dean, A.B.; White, J.L.; Limberger, R.; Sommer, J.N.; Ostrowski, S.; Wong, S.J.; Backenson, P.B.; et al. Zika Virus Testing Considerations: Lessons Learned from the First 80 Real-Time Reverse Transcription-PCR-Positive Cases Diagnosed in New York State. J. Clin. Microbiol. 2017, 55, 535–544.
  59. Singh, R.K.; Dhama, K.; Karthik, K.; Tiwari, R.; Khandia, R.; Munjal, A.; Iqbal, H.M.N.; Malik, Y.S.; Bueno-Marí, R. Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update. Front. Microbiol. 2018, 8, 2677.
  60. Basile, A.J.; Ao, J.; Horiuchi, K.; Semenova, V.; Steward-Clark, E.; Schiffer, J. Performance of InBios ZIKV Detect™ 2.0 IgM Capture ELISA in two reference laboratories compared to the original ZIKV Detect™ IgM Capture ELISA. J. Virol. Methods 2019, 271, 113671.
  61. Munoz-Jordan, J.L. Diagnosis of Zika Virus Infections: Challenges and Opportunities. J. Infect. Dis. 2017, 216, S951–S956.
  62. Peters, R.; Stevenson, M. Zika virus diagnosis: Challenges and solutions. Clin. Microbiol. Infect. 2019, 25, 142–146.
  63. Atif, M.; Azeem, M.; Sarwar, M.R.; Bashir, A. Zika virus disease: A current review of the literature. Infection 2016, 44, 695–705.
  64. Van Rompay, K.K.A.; Keesler, R.I.; Ardeshir, A.; Watanabe, J.; Usachenko, J.; Singapuri, A.; Cruzen, C.; Bliss-Moreau, E.; Murphy, A.M.; Yee, J.L.; et al. DNA vaccination before conception protects Zika virus–exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Sci. Transl. Med. 2019, 11, eaay2736.
  65. da Silva, S.; Oliveira Silva Martins, D.; Jardim, A.C.G. A Review of the Ongoing Research on Zika Virus Treatment. Viruses 2018, 10, 255.
  66. Singh, R.K.; Dhama, K.; Khandia, R.; Munjal, A.; Karthik, K.; Tiwari, R.; Chakraborty, S.; Malik, Y.S.; Bueno-Marí, R. Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates. Front. Microbiol. 2018, 9, 87.
  67. Igbinosa, I.I.; Rabe, I.B.; Oduyebo, T.; Rasmussen, S.A. Zika Virus: Common Questions and Answers. Am. Fam. Physician 2017, 95, 507–513.
  68. Meghani, Z.; Boëte, C. Genetically engineered mosquitoes, Zika and other arboviruses, community engagement, costs, and patents: Ethical issues. PLoS Negl. Trop. Dis. 2018, 12, e0006501.
  69. Poland, G.A.; Ovsyannikova, I.G.; Kennedy, R.B. Zika Vaccine Development: Current Status. Mayo Clin. Proc. 2019, 94, 2572–2586.
  70. das Neves Almeida, R.; Racine, T.; Magalhães, K.G.; Kobinger, G.P. Zika Virus Vaccines: Challenges and Perspectives. Vaccines 2018, 6, 62.
  71. Pattnaik, A.; Sahoo, B.R.; Pattnaik, A.K. Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines 2020, 8, 266.
  72. Devillers, J. Repurposing drugs for use against Zika virus infection. SAR QSAR Environ. Res. 2018, 29, 103–115.
  73. Gardinali, N.R.; Marchevsky, R.S.; Oliveira, J.M.; Pelajo-Machado, M.; Kugelmeier, T.; Castro, M.P.; Silva, A.C.A.; Pinto, D.P.; Fonseca, L.B.; Vilhena, L.S.; et al. Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys. Antivir. Res. 2020, 182, 104859.
  74. Mesci, P.; Macia, A.; Moore, S.M.; Shiryaev, S.A.; Pinto, A.; Huang, C.-T.; Tejwani, L.; Fernandes, I.R.; Suarez, N.A.; Kolar, M.J.; et al. Blocking Zika virus vertical transmission. Sci. Rep. 2018, 8, 1218.
  75. Rehman, A.; Ashfaq, U.A.; Javed, M.R.; Shahid, F.; Noor, F.; Aslam, S. The Screening of Phytochemicals Against NS5 Polymerase to Treat Zika Virus Infection: Integrated Computational Based Approach. Comb. Chem. High Throughput Screen 2022, 25, 738–751.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback